EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient‐Derived Liver Disease Models

Adhuresa Ramosaj, Mariia Borsuk, Jarl Underhaug, Déborah Mathis, Shirou Matsumoto, Adrian Keogh, Vanessa Banz, Amit V Pandey, Nadine Gougeard, Vicente Rubio, Aurora Martinez, Gabriella Allegri und 4 weitere

Journal of Inherited Metabolic Disease · 2025

DOI: 10.1002/jimd.70043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Adhuresa Ramosaj und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern,…. Hauptthemen laut MEDLINE: Ornithine Carbamoyltransferase, Ornithine Carbamoyltransferase Deficiency Disease, Urea Cycle Disorders, Inborn, Molecular Chaperones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Stiftung für Medizinisch-Biologische Forschung, Fondazione Ettore e Valeria Rossi, Batzenbär-Stiftung des Inselspitals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urea cycle disorders (UCDs) are inherited diseases causing recurrent life‐threatening metabolic decompensations due to impaired hepatic ammonia detoxification and decreased ureagenesis. Ornithine transcarbamylase (OTC) deficiency (OTCD) is X‐linked and the most common and often fatal UCD. In male hemizygous patients, disease severity primarily depends on the pathogenic sequence variant, while in heterozygous females, disease severity also depends on the X‐chromosomal inactivation (XCI) pattern. Females with unfavorable XCI predominantly expressing the mutant OTC protein may be severely affected. Here, we investigated a novel treatment strategy for OTCD since there is an unmet need for better therapies. In the first step, we performed a high throughput screening (HTS) using a diversity library with 10 000 chemical compounds to identify pharmacological chaperone (PC) candidates that stabilize purified wild‐type OTC. Stratification of our HTS results revealed five potential PCs, which were selected for further experimentation in cellular systems using primary human hepatocytes (PHHs) and human induced pluripotent stem cell (hiPSC)‐derived hepatocytes (hiPSC‐Heps) from healthy controls and OTCD patients. Two PCs—PC1 and PC4—increased OTC protein stability and activity in control hiPSC‐Heps, while PC4 in addition increased OTC activity in patient‐derived PHHs from a female OTCD patient with unfavorable XCI. Finally, PC1 and PC4 both significantly increased ureagenesis in patient‐derived PHHs. To conclude, we identified two PCs that stabilized wild‐type OTC and enhanced enzyme activity and ureagenesis. Our work suggests that PCs could provide a novel treatment strategy for OTCD specifically in females with unfavorable XCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ornithine CarbamoyltransferaseOrnithine Carbamoyltransferase Deficiency DiseaseUrea Cycle Disorders, InbornMolecular ChaperonesLiver DiseasesHumansFemaleHepatocytesMaleEnzyme StabilityInduced Pluripotent Stem CellsHigh-Throughput Screening AssaysUreaX Chromosome InactivationMutation

Stichwörter der Autor:innen

human induced pluripotent stem cellshuman induced pluripotent stem cell‐derived hepatocytesliver disease modelornithine transcarbamylase deficiencypharmacological chaperonesurea cycle disorders

Substanzen

Ornithine CarbamoyltransferaseMolecular ChaperonesUreaOTC protein, human

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Biomedicine, University of Bergen, Bergen, Norway.
  • Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Biomedical Research, University of Bern, Bern, Switzerland.

ORCID-Profile: Alexander Laemmle

Förderung

  • Novartis Stiftung für Medizinisch-Biologische Forschung
  • Fondazione Ettore e Valeria Rossi
  • Batzenbär-Stiftung des Inselspitals
  • Swiss National Science Foundation
  • Fundación Ramón Areces
  • Research Counsil of Norway
  • University of Bergen
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Ramosaj, A., Borsuk, M., Underhaug, J., Mathis, D., Matsumoto, S., Keogh, A., Banz, V., Pandey, A. V., Gougeard, N., Rubio, V., Martinez, A., Allegri, G., Poms, M., Thöny, B., Häberle, J., & Laemmle, A. (2025). Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient‐Derived Liver Disease Models. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70043

Vancouver

Ramosaj A, Borsuk M, Underhaug J, Mathis D, Matsumoto S, Keogh A, et al. Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient‐Derived Liver Disease Models. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70043

BibTeX
@article{Ramosaj2025,
  author = {Ramosaj, Adhuresa and Borsuk, Mariia and Underhaug, Jarl and Mathis, Déborah and Matsumoto, Shirou and Keogh, Adrian and Banz, Vanessa and Pandey, Amit V and Gougeard, Nadine and Rubio, Vicente and Martinez, Aurora and Allegri, Gabriella and Poms, Martin and Thöny, Beat and Häberle, Johannes and Laemmle, Alexander},
  title = {Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient‐Derived Liver Disease Models},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  doi = {10.1002/jimd.70043}
}
Kostenlos starten →